Your doctor prescribed Zepbound® or Ozempic®, the pharmacy called with the price, and your insurance company said no. Now you are staring down an expensive cost for a medication you were told you needed and wondering how to pay for it.
You are not alone, and you are not stuck. Only 19% of firms with 200 or more workers report their largest plan covers GLP-1 drugs for weight loss.1 With coverage this narrow, denials are common, yet in the ACA marketplace, fewer than 1% of denied claims are ever appealed.2 A lot of people accept a no that could have been overturned.
This guide lays out every real option: get the medication covered, pay less for it, or take a route that does not need insurance at all. Frustrating as this is, there is almost always a path forward.
A quick comparison of your real options:
| Option | What it does | Typical cost | Best for |
|---|---|---|---|
| Appeal the denial | Formal request to reverse an insurer decision | Free (your time) | Anyone with a denial letter and a supportive prescriber |
| Manufacturer savings / self-pay | LillyDirect (Zepbound) or NovoCare (Wegovy®) direct-purchase programs | Discounted vs. cash price; verify current figures | People able to self-pay a reduced monthly cost |
| Compounded semaglutide | Custom-made version from a compounding pharmacy | Lower, but FDA-restricted since Feb 2025 | Patients working with a licensed provider and PCAB-accredited pharmacy |
| Medicare GLP-1 Bridge Pilot | Time-limited Medicare pilot covering select GLP-1s | $50/month flat copay (does not count toward deductible or cap) | Medicare Part D enrollees who meet BMI and condition criteria |
| Employer plan advocacy | Requesting your HR team add or reconsider GLP-1 coverage | Free (your time) | Employees whose company self-funds benefits |
| Prescriber-guided alternatives | Switching within the class or trying a different medication | Varies by drug and coverage | People whose denial is drug-specific, not class-wide |
| Calocurb (Amarasate) | Natural, no-prescription supplement; a 24-week RCT showed 4.3% weight loss with lean muscle preserved | $1 per capsule; bottles from $89.99 | People wanting to skip insurance and prescriptions entirely |
*Pricing is approximate and subject to change. Figures reflect publicly available retail prices at time of publication and may vary based on pharmacy and location.
Why Won't My Insurance Cover Ozempic or Zepbound?
The single biggest reason: most plans cover GLP-1 drugs for type 2 diabetes but not for weight loss. Ozempic is FDA-approved for diabetes, and Zepbound is approved for chronic weight management. If your plan excludes weight-loss medications, a Zepbound prescription can be denied even when it is medically appropriate.
The Kaiser Family Foundation reports that 19% of large employer plans cover GLP-1 drugs for weight loss in 2025 — 16% at firms with 200 to 999 employees, 30% at 1,000 to 4,999, and 43% at firms with 5,000 or more — compared with the vast majority that cover them for diabetes.3 That gap is where most denials come from.
Beyond outright exclusions, denials fall into a few familiar buckets. The denial letter you received will tell you which one applies, and the fix depends on the type.
- Formulary exclusion. The drug is not on your plan's covered list. Solution: request a formulary exception.
- Prior authorization not met. Your plan requires documentation before approving. Solution: submit the missing paperwork with your prescriber.
- Step therapy required. You must try a cheaper option first. Solution: request a step-therapy exception if a cheaper option is inappropriate for you.
- Off-label use. For example, using Ozempic for weight loss when your plan only covers it for diabetes. Solution: switch to the on-label drug for your goal, or appeal with a letter of medical necessity.
Identify your denial type first. Every path in this guide gets easier when you know exactly what you are working with.
Option 1: Appeal the Denial (It Works More Often Than You Think)
An appeal is a formal request asking your insurer to reverse its decision. It is free, and it is one of the most underused tools in the system: fewer than 1% of denied ACA marketplace claims are ever appealed.4 Filing an appeal doesn't guarantee reversal, but it costs nothing to try, and it forces the insurer to reconsider.
You have deadlines, so act quickly. Most plans allow 180 days to file an internal appeal from the date of denial, and shorter windows for external review.
Match your appeal to your denial type
- Formulary exception. Your prescriber writes to your insurer explaining why the excluded drug is medically necessary for you.
- Step-therapy exception. Your prescriber documents why cheaper alternatives are inappropriate. For example, you have already tried them, or they carry known risks for you.
- Letter of medical necessity. A detailed letter tying your specific health history, BMI, comorbidities, and prior treatment attempts to the requested drug.
How to file
- Read your denial letter carefully. It names the reason and the appeal deadline.
- Ask your prescriber's office to submit the appeal on your behalf. Most do this routinely.
- If the internal appeal fails, request an external review by an independent third party.
- Keep copies of everything: denial letters, prescriber notes, medical records, and every submission you send.
If you would rather not fight, that is a valid choice. The next sections cover options that skip the insurance battle entirely.
Option 2: Lower the Cash Price
If coverage is not coming through, several programs can meaningfully reduce what you pay out of pocket. Prices and eligibility change often, so confirm current figures at the source before you commit.
Manufacturer savings cards and self-pay
LillyDirect offers direct-purchase pricing for Zepbound, typically at a lower monthly cost than retail cash price. NovoCare offers a similar direct-purchase option for Wegovy. Both bypass insurance entirely. You pay the manufacturer, not the pharmacy.
For a full cost breakdown, including how these programs stack up against retail and compounded options, read our guide to affordable alternatives to Ozempic. And if an insurance denial is what started your search, that guide pairs well with this one.
Compounded semaglutide: cheaper, with caveats
Compounded semaglutide made GLP-1 medications available to many people at a fraction of the brand price during a nationwide shortage. In February 2025, the FDA ended the semaglutide shortage designation, and enforcement against large-scale compounding has tightened since, with the FDA proposing in April 2026 to permanently bar bulk compounding of the drug altogether.5 If you are considering compounded semaglutide, only work with a licensed provider and a PCAB-accredited compounding pharmacy. Ask specifically what active ingredient is used and where it is sourced. Compounded drugs are not FDA-approved and do not go through the same quality-control review as brand-name medications.
Medicare pathways
For years, Medicare did not cover GLP-1 drugs for weight loss at all. That is changing, for a limited window.
The pilot began July 1, 2026. Covered medications include Wegovy (injection and oral), Zepbound KwikPen, and Foundayo®.7
To qualify, you must be enrolled in a Part D plan (standalone or through a Medicare Advantage plan with drug coverage) and meet one of the following criteria. Eligibility is based on your BMI when you started GLP-1 therapy, not today:
- BMI 35 or higher qualifies on its own.
- BMI 30 or higher with certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease (stage 3a or above).
- BMI 27 or higher with prediabetes, a prior heart attack or stroke, or blocked arteries.
Two catches worth knowing. The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. And if you already qualify for GLP-1 coverage under Part D through type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, you get coverage that way instead, not through the Bridge.8
A Kaiser Family Foundation analysis estimates that nearly four million Medicare beneficiaries met the Bridge program's eligibility criteria based on 2023 data (Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge, KFF, 2026).
Employer plans
If your coverage comes through work, your HR or benefits team may be able to add or reconsider GLP-1 coverage. Many plans exclude these drugs by default, and some employers have added them after employees requested them. This is not a guarantee, but it is a practical step, and a polite email to HR with your prescriber's supporting letter costs nothing to try.
Option 3: Talk to Your Prescriber About Alternatives
Sometimes the fastest path is not fighting the denial. It is switching to a covered option. Ask your prescriber whether a different GLP-1, a different dose, or an on-label indication might be appropriate for you.
- Switching within the class: if your plan covers one GLP-1 but not another, moving to the covered drug may resolve the issue.
- Different indication: if you have type 2 diabetes as well as weight to lose, the diabetes indication may unlock coverage.
- Different dose or formulation: some plans cover certain doses and not others.
The clinical decision belongs with your prescriber. Come to the conversation with what your plan covers and what it does not, so your doctor has real information to work with.
Option 4: A Route That Doesn't Need Insurance at All
If you would rather not spend months appealing a denial, or pay $1,000+ out of pocket while you sort it out, there is a fourth option. Skip the prescription route entirely.
Calocurb is a natural supplement built around Amarasate, a patented Hop Bitter Extract that activates the bitter taste receptors in your gut. Those receptors signal your body to release its own GLP-1, CCK, and PYY, the three satiety hormones (the Triple Satiety Hormones) targeted by prescription GLP-1 drugs, but through your body's own pathway. No prescription. No insurance. No injections.
For a deeper comparison of natural and injectable approaches, see our guide on natural vs. injectable GLP-1 approaches.
What the clinical evidence shows
Calocurb's active ingredient has now been studied in four published human clinical trials. The earlier three showed how Amarasate changes gut hormone release and short-term appetite. The most recent, a 24-week randomized controlled trial, shows what that translates to over months.
In the hormone and meal study in men, taking Amarasate one hour before a meal was followed by a post-meal rise in GLP-1 and CCK and an 18% reduction in calorie intake at the next meal.9
In a 24-hour water-only fasting study in men, taking Amarasate produced a 30% reduction in hunger during the late part of the fast.10
A separate fasting study in women found a 14.3% reduction in calorie intake at the meal following the fast, alongside significant reductions in hunger and food cravings.11
The newest trial, a 24-week randomized, double-blind, placebo-controlled study in 128 adults with a BMI of 25 to 35, measured what happens to body composition over months, not minutes. Participants taking Amarasate (500 mg daily, taken one hour before two main meals) lost 4.3% of body weight compared with 0.5% on placebo, with 9.9 lb of fat mass lost versus 1.5 lb on placebo, and a 5.0 sq in reduction in visceral fat versus 1.4 sq in on placebo. Lean muscle was preserved and slightly increase in muscle mass in the Calocurb group compared to placebo.12
You can read the full evidence base on the Calocurb Science page.
Honest framing
Calocurb is not a pharmaceutical-strength GLP-1 medication. The value here is different. Calocurb reframes the goal from weight loss alone to weight health, protecting lean muscle while reducing fat and visceral fat. It is an accessible, plant-based option for people who want appetite support without the prescription or insurance route, and a useful support during the transition off injectables. If you are coming off a GLP-1 and worried about appetite rebound, see our guide on what happens when you stop injectable weight loss medications.
No prescription. No insurance battle.
A natural GLP-1 alternative backed by clinical trials
Calocurb activates your body's own appetite hormones through clinically studied Amarasate. No injections, no insurer approval required.
Free Ways to Support Your Own GLP-1 While You Decide
While you sort through insurance, appeals, or alternatives, some of the highest-leverage moves cost nothing. Your body already makes GLP-1 in response to what and how you eat. A few habits reliably strengthen that signal.
- Protein first. Eating protein and vegetables before starchy carbs can lower post-meal glucose and insulin.13
- Fermentable fiber. Beans, oats, and other fiber-rich foods produce short-chain fatty acids in the gut that stimulate GLP-1 release.
- Resistance training. Building muscle improves insulin sensitivity and blood sugar control, which supports appetite regulation.
- Sleep. Consistent 7- to 9-hour sleep windows blunt the hunger hormones that spike after a short night.
None of these replaces medical treatment for obesity, but all of them work with, not against, whatever option you choose.
